Kintegral Advisory
BIIB icon

Kintegral Advisory’s Biogen BIIB Stock Holding History

Kintegral Advisory’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.08M Buy
18,048
+102
+0.6% +$21.6K 0.32% 76
2026
Q2 		$3.88M Hold
17,946
– – 0.31% 79
2026
Q1 		$3.29M Sell
17,946
-796
-4% -$147K 0.31% 87
2025
Q4 		$3.3M Sell
18,742
-512
-3% -$83.6K 0.28% 93
2025
Q3 		$2.7M Sell
19,254
-86
-0.4% -$11.6K 0.23% 108
2025
Q2 		$2.43M Sell
19,340
-29
-0.1% -$3.61K 0.22% 111
2025
Q1 		$2.65M Sell
19,369
-66
-0.3% -$9.44K 0.27% 101
2024
Q4 		$2.97M Sell
19,435
-905
-4% -$153K 0.28% 97
2024
Q3 		$3.94M Sell
20,340
-266
-1% -$55.6K 0.36% 86
2024
Q2 		$4.78M Buy
20,606
+7,885
+62% +$1.71M 0.46% 61
2024
Q1 		$2.74M Sell
12,721
-40
-0.3% -$9.37K 0.27% 96
2023
Q4 		$3.3M Sell
12,761
-81
-0.6% -$19.9K 0.37% 81
2023
Q3 		$3.3M Sell
12,842
-8
-0.1% -$2.14K 0.41% 70
2023
Q2 		$3.66M Hold
12,850
– – 0.43% 70
2023
Q1 		$3.57M Sell
12,850
-690
-5% -$191K 0.46% 69
2022
Q4 		$3.75M Buy
13,540
+5,262
+64% +$1.49M 0.5% 64
2022
Q3 		$2.21M Hold
8,278
– – 0.31% 87
2022
Q2 		$1.69M Buy
8,278
+175
+2% +$35.8K 0.22% 110
2022
Q1 		$1.71M Buy
8,103
+182
+2% +$39.6K 0.19% 117
2021
Q4 		$1.9M Hold
7,921
– – 0.2% 115
2021
Q3 		$2.24M Hold
7,921
– – 0.26% 93
2021
Q2 		$2.74M Hold
7,921
– – 0.32% 78
2021
Q1 		$2.22M Hold
7,921
– – 0.28% 91
2020
Q4 		$1.94M Hold
7,921
– – 0.26% 97
2020
Q3 		$2.25M Sell
7,921
-255
-3% -$71.1K 0.34% 75
2020
Q2 		$2.19M Hold
8,176
– – 0.35% 75
2020
Q1 		$2.59M Buy
8,176
+916
+13% +$278K 0.5% 53
2019
Q4 		$2.15M Hold
7,260
– – 0.39% 76
2019
Q3 		$1.69M Hold
7,260
– – 0.34% 86
2019
Q2 		$1.7M Hold
7,260
– – 0.34% 85
2019
Q1 		$1.72M Sell
7,260
-463
-6% -$146K 0.36% 83
2018
Q4 		$2.32M Buy
+7,723
New +$2.46M 0.69% 37

Other funds holding BIIB

Artemis Investment Management
Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return
Beau Ventures, LLc
Beau Ventures, LLc Pittsford, New York $1.06B AUM 83.06% 1-Year Est. Return
Banque Pictet & Cie
Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return
Gateway Investment Advisers
Gateway Investment Advisers Cincinnati, Ohio $11B AUM 34.31% 1-Year Est. Return
North Growth Management
North Growth Management Vancouver, British Columbia, Canada $743M AUM 74.29% 1-Year Est. Return
CIM
Contravisory Investment Management Norwell, Massachusetts $552M AUM 32.44% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
Czech National Bank
Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return
CWA Asset Management Group
CWA Asset Management Group Naples, Florida $3.39B AUM 25.16% 1-Year Est. Return
MN Services Vermogensbeheer
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return

Kintegral Advisory's BIIB Position: Q3 2026 in Review

Kintegral Advisory increased its Biogen (BIIB) stake by 0.57% in Q3 2026, buying an estimated $21.6K and bringing the position to 18,048 shares worth $4.08M. The position accounts for 0.32% of the portfolio, ranked #76.

Kintegral Advisory first reported a position in BIIB in Q4 2018 and has held it in 32 quarters since. The position peaked at $4.78M in Q2 2024. 153 funds tracked by Wall St. Rank hold BIIB as of Q3 2026.

  • Kintegral Advisory held 18,048 shares of Biogen worth $4.08M as of Q3 2026.
  • Kintegral Advisory bought 102 Biogen shares in Q3 2026, an estimated $21.6K.
  • Biogen made up 0.32% of Kintegral Advisory's portfolio in Q3 2026, its #76 holding.
  • Kintegral Advisory first reported a position in Biogen in Q4 2018 and has held it in 32 quarters since.
  • Kintegral Advisory's Biogen position peaked at $4.78M in Q2 2024.
  • 153 funds tracked by Wall St. Rank held Biogen as of Q3 2026.

Based on Kintegral Advisory's 13F filing for Q3 2026, filed 16 Oct 2026.